Clinical trials · Raleigh–Durham, NC
Allergy clinical trials in Raleigh–Durham
We’re tracking 20 recruiting allergy studies with a site in or near Raleigh–Durham — including Phase 1, Phase 1/Phase 2, Phase 2 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies near Raleigh–Durham
- NCT07110532RecruitingPhase 1
A study of flu virus exposure in healthy adults
This trial tests how the body reacts to a specific flu virus (pH1N1) in a controlled setting. Healthy volunteers are exposed to the virus to help researchers understand the infection and test treatments. You will be monitored closely and given antiviral medication if needed.
Durham, North CarolinaAges 18–55 - NCT06075745RecruitingPhase 2
CMV Vaccine Study for Liver Transplant Candidates
This trial tests a vaccine to prevent cytomegalovirus (CMV) infection in people awaiting a first liver transplant. You may be eligible if you have never been infected with CMV and are scheduled to receive a liver transplant within the next 1 to 12 months.
Durham, North CarolinaAges 18 years+ - NCT01186913Enrolling by invitation
Natural history study for severe combined immune deficiency (SCID)
This study follows children and adults with SCID and related immune disorders to understand how the illness behaves over time. It also helps researchers learn which testing results and genetic types of SCID match different treatment plans.
Durham, North CarolinaAges Any age - NCT04047628RecruitingPhase 3
MS patients with active relapsing disease comparing two treatment plans
This Phase 3 study compares the best standard MS treatment (chosen by your doctors) versus an approach called autologous hematopoietic stem cell transplant (AHSCT) for people with highly active, treatment-resistant relapsing multiple sclerosis. It aims to see which option controls MS disease activity better and keeps you safer over time.
Durham, North CarolinaAges 18–55 - NCT05671757RecruitingPhase 1/Phase 2
Daratumumab for primary antiphospholipid syndrome
This early-phase study tests daratumumab, an immune-targeting drug, for people with primary antiphospholipid syndrome (APS). It aims to see whether it can reduce APS activity and improve outcomes while you continue your usual blood-thinning treatment.
Durham, North CarolinaAges 18–65 - NCT06476132RecruitingPhase 2
Belumosudil for lung transplant patients at risk of chronic rejection
This trial tests whether the drug Belumosudil can help prevent chronic lung rejection in people who recently had a lung transplant and showed signs of early rejection. It may improve long-term lung health.
Durham, North CarolinaAges 12 years+ - NCT06055608RecruitingPhase 2
Improving kidney transplant outcomes in teens and young adults
This trial tests a new approach to help teenagers and young adults keep their first kidney transplant working well. It looks at how to improve long-term success by carefully managing the immune system around the time of transplant.
Durham, North CarolinaAges 13–20 - NCT05917522RecruitingPhase 2
Biomarker-guided changes to anti-rejection medicines after kidney transplant
This Phase 2 study looks at whether blood test “biomarkers” can guide safely changing anti-rejection medicines after an ABO-compatible kidney transplant. It may help some people reduce certain medicines while keeping the new kidney protected from rejection.
Durham, North CarolinaAges 18–70 - NCT06033196RecruitingPhase 2
Tocilizumab to prevent lung transplant rejection
This trial tests a drug called tocilizumab (brand name Actemra) to see if it helps prevent rejection after lung transplantation. Tocilizumab targets part of the immune system that may otherwise attack the new lungs.
Durham, North CarolinaAges 12–75 - NCT06280950RecruitingPhase 2
Reducing immune-suppressing drugs after liver transplant with everolimus
This study tests if adding everolimus can allow liver transplant recipients to safely reduce their usual immune-suppressing medicines. It aims to protect kidney function while preventing organ rejection.
Durham, North CarolinaAges 18 years+ - NCT06918990RecruitingPhase 1
CarBel for antibody-mediated rejection after kidney transplant
This study tests a new drug called CarBel to treat antibody-mediated rejection in kidney transplant patients. The goal is to see if it can help stop the rejection and protect your new kidney.
Durham, North CarolinaAges 18–75 - NCT07059091RecruitingPhase 2
Omalizumab for COPD with allergies
This trial tests if omalizumab, an allergy medication, can help people with COPD who have allergies to common indoor triggers like cat, dog, mouse, cockroach, or dust mite. It aims to reduce flare-ups and improve breathing.
Durham, North CarolinaAges 40 years+ - NCT07580898RecruitingPhase 1
Testing MOON101 Safety for Peanut Allergy Treatment
This study tests whether a new drug called MOON101 is safe for people with peanut allergies. The goal is to see if it might help your immune system tolerate peanuts better and reduce severe allergic reactions.
Chapel Hill, North CarolinaAges 4–55 - NCT06943534RecruitingPhase 2
Omalizumab for severe food allergies: weight-based dosing study
This trial tests if omalizumab (a drug that blocks allergy reactions) can help people with multiple food allergies. You might qualify if you have severe allergies to at least two foods like peanut, tree nuts, egg, or milk.
Chapel Hill, North CarolinaAges 1–55 - NCT07216794RecruitingPhase 2
Alendronate trial to reduce hidden HIV
This study tests if alendronate, a bone-strengthening medicine, can shrink the reservoir of HIV that stays in your body even when on treatment. You must have well-controlled HIV on antiretroviral therapy for at least one year but no more than ten years, and meet specific health requirements.
Chapel Hill, North CarolinaAges 18–65 - NCT05719441RecruitingPhase 2
Antibodies plus early HIV treatment to try for HIV remission
This study tests whether giving special HIV-fighting antibodies along with starting standard HIV medicine soon after infection can help you reach “HIV remission.” It may reduce or delay the return of detectable virus, but you must be willing to follow close monitoring and specific study steps.
Chapel Hill, North CarolinaAges 18–70 - NCT07015996RecruitingPhase 2
Tezepelumab for peanut allergy oral immunotherapy
This trial tests whether adding tezepelumab (a biologic drug) to peanut oral immunotherapy can help people with peanut allergy better tolerate small amounts of peanut protein without having an allergic reaction.
Chapel Hill, North CarolinaAges 12–55 - NCT03949855RecruitingPhase 2
Belimumab plus rituximab for primary membranous nephropathy
This study tests whether adding belimumab to rituximab helps people with primary membranous nephropathy (a kidney disease) that has the right blood test marker and specific protein levels. The goal is to improve kidney outcomes and reduce disease activity while keeping treatment safe.
Chapel Hill, North CarolinaAges 18–75 - NCT06456541Recruiting
Testing a new infant formula for children with cow's milk allergy
This study tests a new formula designed for children diagnosed with cow's milk allergy. It evaluates whether the formula is safe and well-tolerated.
Chapel Hill, North CarolinaAges 3 months–12 years - NCT07220811RecruitingPhase 2
Testing a new drug for food allergies
This trial tests a new medication called RPT904 in people with IgE-mediated food allergies to foods like peanut, milk, egg, cashew, or walnut. The goal is to see if it reduces allergic reactions when you eat a small amount of the food.
Chapel Hill, North CarolinaAges 12–55
Hear when a new Allergy trial opens near Raleigh–Durham, NC
We’ll email you when one opens near Raleigh–Durham, NC — at most once a week, no account needed, unsubscribe anytime.
Allergy trials in other cities
Where these studies are running near Raleigh–Durham
Institutions with a site for the recruiting allergy studies listed above.
- Duke University Medical Center · 9 studies
- University of North Carolina at Chapel Hill · 5 studies
- Duke University · 2 studies
- Duke Vaccine and Trials Unit
- North Carolina Children's Hospital
- UNC Clinical and Translational Research Center
- UNC School of Medicine
What taking part in a allergy study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Looking wider? See all recruiting allergy studies in North Carolina.
Common questions
- Are there allergy clinical trials near Raleigh–Durham?
- Yes. We're currently tracking 20 recruiting allergy studies with a site near Raleigh–Durham, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a allergy study near Raleigh–Durham?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Raleigh–Durham to take part?
- Not necessarily. These studies have a site near Raleigh–Durham, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a allergy trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New allergy studies open near Raleigh–Durham regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.